David Pendarvis Net Worth

The estimated Net Worth of David Pendarvis is at least $19.8 Million dollars as of 12 April 2024. Mr. Pendarvis owns over 328 units of Resmed stock worth over $1,247,907 and over the last 21 years he sold RMD stock worth over $15,813,476. In addition, he makes $2,720,760 as Chief Administrative Officer, Global General Counsel und Secretary at Resmed.

Mr. Pendarvis RMD stock SEC Form 4 insiders trading

David has made over 151 trades of the Resmed stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 328 units of RMD stock worth $76,998 on 12 April 2024.

The largest trade he's ever made was exercising 87,500 units of Resmed stock on 14 July 2011 worth over $1,840,125. On average, David trades about 5,484 units every 31 days since 2003. As of 12 April 2024 he still owns at least 4,934 units of Resmed stock.

You can see the complete history of Mr. Pendarvis stock trades at the bottom of the page.

David Pendarvis biography

David Pendarvis J.D. serves as Chief Administrative Officer, Global General Counsel, Secretary of the Company. Mr. Pendarvis was a partner in the law firm Gray Cary Ware & Freidenrich LLP. He specialised in intellectual property and general business litigation. he was a partner at Gibson, Dunn & Crutcher LLP. he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California. Mr. Pendarvis was elected to the board of directors of WD-40 Company (NAS DAQ: WDFC). He has also served on the board of directors of the San Diego Regional Chamber of Commerce. he was a director of the Corporate Directors Forum. he was a director on the board of Sequenom, Inc. Mr. Pendarvis holds a bachelor of arts from Rice University; a juris doctor, cum laude, from the University of Texas School of Law; and a master of science in executive leadership from the University of San Diego.

What is the salary of David Pendarvis?

As the Chief Administrative Officer, Global General Counsel und Secretary of Resmed, the total compensation of David Pendarvis at Resmed is $2,720,760. There are 6 executives at Resmed getting paid more, with Michael Farrell having the highest compensation of $10,429,800.

How old is David Pendarvis?

David Pendarvis is 61, he's been the Chief Administrative Officer, Global General Counsel und Secretary of Resmed since 2011. There are 7 older and 14 younger executives at Resmed. The oldest executive at Resmed Inc. is Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD, 79, who is the Founder & Non-Exec. Chairman.

What's David Pendarvis's mailing address?

David's mailing address filed with the SEC is C/O: WD-40 COMPANY, 9715 BUSINESSPARK AVENUE, SAN DIEGO, CA, 92131.

Insiders trading at Resmed

Over the last 22 years, insiders at Resmed have traded over $250,830,262 worth of Resmed stock and bought 10,000 units worth $424,500 . The most active insiders traders include Peter C Farrell, Gary W Pace und David Pendarvis. On average, Resmed executives and independent directors trade stock every 7 days with the average trade being worth of $3,005,701. The most recent stock trade was executed by Brett Sandercock on 9 September 2024, trading 1,000 units of RMD stock currently worth $246,420.

What does Resmed do?

at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

Complete history of Mr. Pendarvis stock trades at WD-40 Co und Resmed

Resmed executives and stock owners

Resmed executives and other stock owners filed with the SEC include:

• Michael Farrell,
  Chief Executive Officer, Director
• Robert Douglas,
  President, Chief Operating Officer
• Jim Hollingshead,
  President – sleep and respiratory care business
• Rajwant Sodhi,
  President – Software as a Service Business (SaaS)
• Brett Sandercock,
  Chief Financial Officer
• Michael J. Farrell BE, SM, MBA,
  CEO & Director
• David Pendarvis,
  Chief Administrative Officer, Global General Counsel, Secretary
• Michael J. Farrell BE, MBA, SM,
  CEO & Director
• Robert A. Douglas,
  Pres & COO
• Dr. James R. Hollingshead Ph.D.,
  Pres of Sleep & Respiratory Care Bus.
• Brett A. Sandercock,
  Chief Financial Officer
• Peter Farrell,
  Non-Executive Chairman of the Board
• Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD,
  Founder & Non-Exec. Chairman
• Dr. Peter C. Farrell A.M., B.E., Ph.D., BE (Hons), ScD, AM,
  Founder & Non-Exec. Chairman
• Ronald Taylor,
  Lead Independent Director
• Carol Burt,
  Independent Director
• Richard Sulpizio,
  Independent Director
• Harjit Gill,
  Independent Director
• Jan De Witte,
  Independent Director
• Karen Drexler,
  Independent Director
• Justin Leong,
  President – Asia and Latin America
• Urvashi Tyagi,
  Chief Technology Officer
• Nupur Bhushan,
  Chief People Officer
• David B. Pendarvis,
  Chief Admin. Officer, Global Gen. Counsel & Corp. Sec.
• Amy Wakeham,
  VP of Investor Relations & Corp. Communications
• Constance C. Bienfait,
  Director of Investor Relations
• Kaushik Ghoshal,
  Pres of SaaS Bus. & CTO
• John P Wareham,
  Director
• Christopher G Roberts,
  Director
• Donald Darkin,
  Sr. Vice President, Pat Inter
• Gary W Pace,
  Director
• Anne Reiser,
  President - ResMed Europe
• Richard Mc Hale,
  President, RC Business
• Inc Resmed,
  Director
• James Hollingshead,
  President, Sleep Business
• Kieran Gallahue,
  President, Global
• Paul Eisen,
  Vice President, Europe & Asia
• Donagh Mccarthy,
  Director
• Adrian M Smith,
  CFO
• Klaus H Shindhelm,
  Sr. Vice President, Operations
• Keith Serzen,
  Chief Operating Officer
• Louis A Simpson,
  Director
• Christopher Bartlett,
  Director
• Walter Flicker,
  VP and Asst. Corp. Secretary
• Lasse Beijer,
  COO-Europe
• Stein Jacobsen,
  COO, Europe
• Michael A Quinn,
  Director
• Kaushik Ghoshal,
  President, SaaS Business
• Lucile Blaise,
  President, Sleep & RC Business
• John Hernandez,
  Director
• Desney Tan,
  Director
• Michael J Rider,
  Global General Counsel
• Christopher Del Orefice,
  Director